Press Releases

Press Releases
Date Title and Summary View
Dec 7, 2017 -- Phase III Secondary Endpoint Results Demonstrate A Significantly Higher Disease-free Survival Rate following ABRAXANE as Investigational Therapy in Neoadjuvant Breast Cancer -- NEU-ISENBURG, Germany & SUMMIT, N.J.--(BUSINESS WIRE)-- The German Breast Group (GBG) and Celgene Corporation (N...
Dec 10, 2017 Overall response rate (ORR) of 94% in patients in active dose cohorts (doses above 50 x 106 CAR + T-cells) Complete Response (CR) rate of 56% observed in patients in active dose cohorts Median progression free survival (PFS) not reached with median follow up of 40 weeks in...
FirstPrevious ...
46
Add to Briefcase = add release to Briefcase